Gastric Cancer Drug Pipeline Analysis Report 2025

According to the World Cancer Research Fund International, approximately 968,784 new cases of gastric cancer were diagnosed in 2022 across the globe. Data suggests that gastric cancer ranks among the top three most common cancers in 19 countries and continues to be the leading cause of cancer mortality worldwide. The ongoing development of innovative and novel therapies shows a promising future for gastric cancer treatment.

Report Coverage

The Gastric Cancer Pipeline Report by the publisher gives comprehensive insights on the gastric cancer emerging drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The gastric cancer report insights include the analysis of over 100 pipeline drugs and 50+ companies . Moreover, the analysis based on efficacy and safety measure outcomes published for the trials will be covered including their adverse effects in gastric cancer.

A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing gastric cancer pipeline development activities are covered.

Gastric Cancer Drug Pipeline Outlook

An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors, and Gastrointestinal Stromal Tumors (GIST).

Gastric cancer treatment depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immu notherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.

Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.

The gastric cancer report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.

Gastric Cancer - Drug Pipeline Therapeutic Assessment

This section of the gastric cancer pipeline report covers the analysis of gastric cancer drugs based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analysis based on phase.

Late-Stage Products (Phase III and Phase IV)
Mid-Stage Products (Phase II)
Early-Stage Products (Phase I)
Preclinical and Discovery Stage Products

By Route of Administration

The gastric cancer report assessment report covers 50+ drug analysis based on route of administration.

Oral
Parenteral
Others

Gastric Cancer - Pipeline Assessment Segmentation, By Phases

The gastric cancer pipeline landscape covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II trials cover major share of the total gastric cancer clinical trials conducted.

Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.

Gastric Cancer - Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under gastric cancer clinical assessment include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to analysis, the parenteral route accounted for a major share of gastric cancer clinical trials.

Gastric Cancer - Pipeline Assessment - Competitive Dynamics

The report for the gastric cancer drug pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:

Bristol-Myers Squibb
AstraZeneca
Enzon Pharmaceuticals, Inc.
Amgen
Novartis Pharmaceuticals
Bayer AG
Daiichi Sankyo Co., Ltd.
Eisai Co., Ltd.
F. Hoffmann-La Roche AG
Others

Gastric Cancer - Emerging Drugs Profile

The gastric cancer drug profiles cover the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.

Bemarit uzumab - Amgen

Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.

Everolimus - Novartis Pharmaceuticals

The purpose of the study is to evaluate the efficacy and safety of gastric cancer drug candidate RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.

Trastuzumab - Hoffmann-La Roche

The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate Human HER-2 status in gastric cancer.

DS-8201a (DP1) - Daiichi Sankyo Co., L td.

Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.

Key Questions Answered in the Gastric Cancer - Pipeline Assessment Report

What is the current landscape of gastric cancer pipeline drugs?
Which companies/institutions are developing gastric cancer therapeutic drugs?
How many phase II drugs are currently present in gastric cancer pipeline drugs?
Which company is leading the gastric cancer pipeline development activities?
What is the current gastric cancer commercial assessment?
What are the opportunities and challenges present in the gastric cancer drug pipeline landscape?
What is the efficacy and safety profile of gastric cancer pipeline drugs?
Which companies/institutions are involved in gastric cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
What are the geographies covered for clinical trials in gastric cancer?

Related Reports

Global Gastric Ulcer Treatment Market

North America Gastric Cancer Drugs Market

Global Cancer Therapeutics Market

Global Cancer Immunotherapy Market

This product will be delivered within 3-5 business days.

1 Preface

1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions

2 Executive Summary

3 Overview of Gastric Cancer

3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Gastric Cancer
3.5 Diagnosis
3.6 Treatment

4 Patient Profile

4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate

5 Gastric Cancer: Epidemiology Snapshot

5.1 Gastric Cancer Incidence by Key Markets
5.2 Gastric Cancer- Patients Seeking Treatment in Key Markets

6 Gastric Cancer: Market Dynamics

6.1 Market Drivers and Constraints
6.2 SWOT Analysis

7 Gastric Cancer: Key Facts Covered

7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions

8 Gastric Cancer, Drug Pipeline Assessment

8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class

9 Drug Pipeline Comparative Analysis

9.1 List of Gastric Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)

10 Gastric Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)

10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 XRP6976
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Masitinib
10.2.3 HX008
10.2.4 Tegafur
10.2.5 Other Drug

11 Gastric Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)

11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Pemetrexed
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 MEDI4736
11.2.3 Nab-Paclitaxel
11.2.4 Irinotecan
11.2.5 Other Drugs

12 Gastric Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)

12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Pemetrexed
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Promitil
12.2.3 5-Fluorouracil
12.2.4 Other Drugs

13 Gastric Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)

13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 NK510
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 IM92 CAR-T cells
13.2.3 Tcrx T cell
13.2.4 LCAR-C182A cells
13.2.5 Other Drugs

14 Gastric Cancer, Key Drug Pipeline Companies

14.1 Bristol-Myers Squibb
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AstraZeneca
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Enzon Pharmaceuticals, Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Amgen
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Novartis Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Bayer AG
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Daiichi Sankyo Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Daiichi Sankyo Co., Ltd.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Daiichi Sankyo Co., Ltd.
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments

15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2452EUR$2,789USD£2,113GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€3437EUR$3,909USD£2,961GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4483EUR$5,099USD£3,863GBP